Perspective: repurposed drugs for COVID-19

被引：4

作者：

Na-Bangchang, Kesara ^{[1
]}

Porasuphatana, Supatra ^{[2
]}

Karbwang, Juntra ^{[1
]}

机构：

[1] Thammasat Univ, Drug Discovery & Dev Ctr, Off Adv Sci & Technol, Pathum Thani, Thailand

[2] Khon Kaen Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Toxicol, Khon Kaen, Thailand

来源：

ARCHIVES OF MEDICAL SCIENCE | 2022年 / 18卷 / 05期

关键词：

ivermectin; azithromycin; COVID-19; favipiravir; andrographolide; remdesivir; tocilizumab; TO-MODERATE COVID-19; INTERLEUKIN-6 RECEPTOR INHIBITION; ANDROGRAPHIS-PANICULATA EXTRACT; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; OPEN-LABEL; HOSPITALIZED-PATIENTS; COMMON COLD; KAN JANG; TOCILIZUMAB;

D O I：

10.5114/aoms/152467

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: The article aims to emphasize the necessity of proper research design, both scientifically and ethically, in order to provide good evidence for physicians to base their decisions on when prescribing drug treatment. Methods: Research articles and guidelines related to therapy of COVID- 19 were searched from the PubMed database. Results: Only remdesivir and tocilizumab are medicines that have been approved by the US FDA's decision to approve their clinical use in moderate and severe COVID-19. Conclusions: Favipiravir, ivermectin and andrographolide need further well-conducted research to confirm the efficacy and safety against COVID- 19 at different stages.

引用

页码：1378 / 1391

页数：14

共 50 条

[31] A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19
Costa, Barbara
Vale, Nuno
PHARMACEUTICS, 2021, 13 (06)
[32] Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
Baburaj, Gayathri
Thomas, Levin
Rao, Mahadev
ARCHIVES OF MEDICAL RESEARCH, 2021, 52 (03) : 261 - 269
[33] COVID-19: How Effective Are the Repurposed Drugs and Novel Agents in Treating the Infection?
Suet-May, Chow
Sin-Yee, Kuok
Jia-Qing, Lee
Pey-Wen, Goh
Singh, Harleen Kaur A. P. Ranjit
Zhi-Zheng, Timothy Tan
Foo, Jhi-Biau
Hamzah, Sharina
Sellappans, Renukha
Hui-Yin, Yow
SUDAN JOURNAL OF MEDICAL SCIENCES, 2022, 17 (04): : 498 - 538
[34] Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
Osama A. Badary
The Pharmacogenomics Journal, 2021, 21 : 275 - 284
[35] Potential COVID-19 remedies from repurposed drugs and herbal small RNAs
Yang, Yang
Huang, Fengming
Qiao, Xiangyu
Chen, Sheng
Zhang, Cong
Deng, Xingyu
Gu, Wentao
Peng, Ling
Cao, Mengli
Jiang, Jingmei
Gao, George F.
Liu, Yingxia
Jiang, Chengyu
IUBMB LIFE, 2024,
[36] COVID-19 and antihistaminic drugs - the ENT perspective
Mihai, D.
Berghi, N. O.
Vrinceanu, D.
ALLERGY, 2023, 78
[37] Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials
Paul, Subha Sankar
Biswas, Goutam
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2021, 21 (09) : 1123 - 1143
[38] Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19
Huang, Chen-Tsung
Chao, Tai-Ling
Kao, Han-Chieh
Pang, Yu-Hao
Lee, Wen-Hau
Hsieh, Chiao-Hui
Chang, Sui-Yuan
Huang, Hsuan-Cheng
Juan, Hsueh-Fen
HELIYON, 2020, 6 (12)
[39] Functional respiratory imaging repurposed for COVID-19
van Es, Josien
Meijboom, Lilian J.
THORAX, 2021, 76 (02) : 107 - 107
[40] The safety of ivermectin as a repurposed drug for COVID-19
Wentzel, H.
Wang, J.
Dayanamby, A.
Levi, J.
Pilkington, V.
Ellis, L.
Hill, A.
HIV MEDICINE, 2021, 22 : 224 - 225

← 1 2 3 4 5 →